Hilda Buehler

Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.

Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA.

Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland.

Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland.

Abbott Cardiovascular Systems, Inc. manufactures medical devices. It also makes cardiac and peripheral vascular repair surgical systems. The company was founded in 1978 and is headquartered in Santa Clara, CA.

Nido Biosciences, Inc. focuses on developing small molecule therapeutics for the treatment of neurodegenerative diseases. The company is headquartered in Boston, MA.

Ribometrix, Inc. develops small molecule drugs that target functional RNA structures to create new avenues to treat human disease. The company was founded by Kevin Weeks and Katie Warner and is headquartered in Greenville, NC.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Chorus Group Ltd. provides interior design and refurbishment services. It offer services to leisure, retail and public sectors, commercial offices and hotels. The company was founded on February 26, 1996 and is headquartered in Barnet, the United Kingdom.

Part of Eli Lilly & Co., Lilly Research Laboratories is a company that engages in research and develops medicines. The company is based in Indianapolis, IN.

Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA.

Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd

TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA.

Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA.

Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France.

Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.

Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland.

Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020.

Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts.

Auxogyn, Inc. provides novel scientific and development biotechnology services. It is focused on advancing the field of reproductive health through its uniquely-combined knowledge of early human developmental biology, advanced computer vision technology and best clinical practices. The firm's first product, the Eeva test, is designed to provide quantitative information regarding embryo development to assist IVF clinicians in optimizing the treatment path for their patients undergoing IVF procedures. The company was founded by Renee A. Reijo Pera, Barry Behr, Thomas Baer, Connie Wong, Lissa A. Goldenstein and Kevin Loewke in 2008 and is headquartered in Menlo Park, CA.

Kimotion Technologies Belgium BVBA develops EDA software solutions. It offers solutions for analog and mixed signal ICs including modeling, sizing and layout tools, addressing analog functional blocks. The company's software helps circuit designers to size and lay out complex designs containing thousands of transistors. Kimotion Technologies Belgium was founded by Oscar Buset, Walter Daems, Bart de Smedt, Erik Lauwers, and Wim Verhaegen in May 2003 and is headquartered in Leuven, Belgium.

ReAlta Life Sciences, Inc. is a biotech company dedicated to harnessing the power of immune system through PIC1 technology. The company was founded in 2018 and is headquartered in Norfolk, VA.

Wellington Management Co. LLP (Private Equity) (Wellington Management) is a private equity firm, a subsidiary of Wellington Management Co. LLP founded in 1933. The firm is headquartered in Boston, Massachusetts.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA.